Bioceltix S.A. (BCX.WA)
PLN 119.0
(2.59%)
PLN 119.0
(2.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -15.81 Million PLN | -63.55% |
| 2022 | -9.67 Million PLN | -55.67% |
| 2021 | -6.21 Million PLN | -55.77% |
| 2020 | -3.98 Million PLN | -5.63% |
| 2019 | -3.77 Million PLN | -96.68% |
| 2018 | -1.92 Million PLN | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.56 Million PLN | 9.28% |
| 2024 Q2 | -4.15 Million PLN | 9.1% |
| 2023 FY | -15.81 Million PLN | -63.55% |
| 2023 Q4 | -5.03 Million PLN | -24.0% |
| 2023 Q1 | -2.59 Million PLN | 25.21% |
| 2023 Q3 | -4.06 Million PLN | 1.75% |
| 2023 Q2 | -4.13 Million PLN | -59.37% |
| 2022 Q3 | -2.78 Million PLN | -46.25% |
| 2022 Q2 | -1.9 Million PLN | -25.01% |
| 2022 FY | -9.67 Million PLN | -55.67% |
| 2022 Q4 | -3.46 Million PLN | -24.62% |
| 2022 Q1 | -1.52 Million PLN | 42.61% |
| 2021 Q4 | -2.65 Million PLN | -128.69% |
| 2021 FY | -6.21 Million PLN | -55.77% |
| 2021 Q3 | -1.15 Million PLN | 0.0% |
| 2020 FY | -3.98 Million PLN | -5.63% |
| 2019 FY | -3.77 Million PLN | -96.68% |
| 2018 FY | -1.92 Million PLN | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| BIOTON S.A. | 15.29 Million PLN | 203.43% |
| Captor Therapeutics Spolka Akcyjna | -73.01 Million PLN | 78.334% |
| Mabion S.A. | 55.06 Million PLN | 128.731% |
| Molecure S.A. | -22.1 Million PLN | 28.43% |
| NanoGroup S.A. | -7.9 Million PLN | -100.199% |
| Pharmena S.A. | 34.87 Million PLN | 145.366% |
| Poltreg S.A. | -16.86 Million PLN | 6.182% |
| Pure Biologics Spólka Akcyjna | -31.71 Million PLN | 50.124% |
| Ryvu Therapeutics S.A. | -100.94 Million PLN | 84.329% |
| Synthaverse S.A. | 8.64 Million PLN | 282.949% |
| Urteste S.A. | -6.44 Million PLN | -145.379% |